The prices of 90% of the 200 top-selling patented drug products are cheaper in Canada than in the USA at ex-manufacturers' prices, costing 47% less in total, according to a new international comparison of drug prices in 1994 by Canada's Patent Medicines Prices review Board.
Drug prices in Canada are kept down by the fact that about 35% of all products are purchased through provincial drug plans, says the Board, which also notes that the USA has no government agency to control prices.
The study found that internationally, prices of patented drugs in Canada were 11% below the median prices in other industrialized countries. Prices in Germany and Switzerland were 8% and 13% higher respectively, although prices in italy, France, Sweden and the UK were found to be lower.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze